22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The Nevada Legislature and Gov. Steve Sisolak have recently approved Assembly Bill No. 207 (AB 207),...
Read More >
Section 409A was added to the Tax Code in 2004 to, among other things, limit the ability of companie...
Read More >
It seems likely that in the next few years the United States Supreme Court will decide whether ERISA...
Read More >
Governor delivers budget address - Gov. Phil Scott delivered his budget address on Tuesday, focusin...
Read More >
In April 2011, the U.S. Department of Labor (DOL) requested information from the public on how the D...
Read More >
Financial institutions M&A sector trends: asset/wealth management — H2 2019 and outlook for 2020 - ...
Read More >